Ensol Biosciences Inc. (XKON:140610)

Market Cap	366.40B
Revenue (ttm)	537.46M
Net Income (ttm)	-5.40B
Shares Out	12.38M
EPS (ttm)	-644.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	21,454
Average Volume	25,704
Open	30,000
Previous Close	30,000
Day's Range	29,000 - 30,450
52-Week Range	5,010 - 38,800
Beta	0.94
RSI	46.98
Earnings Date	n/a

About Ensol Biosciences

Ensol Biosciences Inc., a biopharmaceutical company, develops bio drugs for the treatment of degenerative disc, osteoarthritis, cancer, type 1 diabetes, and Alzheimer's dementia diseases. The company’s drug pipeline includes Peniel 2000, which is in Phase III clinical trial for the treatment of degenerative disc disease; Engedi 1000 that is in Phase II clinical trial for the treatment of osteoarthritis; and EAD100, a drug for animal osteoarthritis. It also develops anticancer drugs, such as Charis 1000, which is in Phase I clinical trial for th...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2001
• Country: South Korea
• Stock Exchange: Korea New Exchange
• Ticker Symbol: 140610

Financial Performance

In 2017, Ensol Biosciences's revenue was 537.46 million, an increase of 208.94% compared to the previous year's 173.97 million. Losses were -5.40 billion, -10.94% less than in 2016.